HMG CoA reductase inhibitors (statins) for dialysis patients

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Navaneethan, Sankar D ^a   Nigwekar, Sagar U ^b   Perkovic, Vlado ^c   Johnson, David W ^d   Craig, Jonathan C ^e   Strippoli, Giovanni F M ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c GEORGE INSTITUTE FOR INTERNATIONAL HEALTH   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Antilipemic agents *therapeutic use ; Cholesterol *blood ; Humans; Hydroxymethylglutaryl CoA reductase inhibitors *therapeutic use ; Peritoneal dialysis, continuous ambulatory; Randomized controlled trials as topic; Renal dialysis; Triglycerides *blood

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ATORVASTATIN; ENALAPRIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOLIDAEMIC AGENT; LOW DENSITY LIPOPROTEIN; PLACEBO; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEMODIALYSIS; HUMAN; LIVER FUNCTION TEST; MORTALITY; PERITONEAL DIALYSIS; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70049114003     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004289.pub4     Document Type: Review

References (86)

1. Krane V, Krieter DH, Olschewski M, Maerz W, Mann JFE, Ritz E, et al. Impact of dialyzermembrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]. Journal of the American Society of Nephrology 2006;17(Abstracts):22A. [CENTRAL: CN-00602047]
2. Krane V, MaerzW, Ruf G, Ritz E, Wanner C. Atorvastatin in Type 2 diabetic patients on hemodialysis (4D-study): baseline characteristics and 1st interim analysis. [abstract no: SA-PO897]. Journal of the American Society of Nephrology 2003;14(Nov):496A. [CENTRAL: CN-00550410]
3. Wanner C, Krane V, Marz W, Olschewski M, Asmus HG, Kramer W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney & Blood Pressure Research 2004;27(4):259-266 [MEDLINE: 15316128] (Pubitemid 39279330)
4. * Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine 2005;353(3):238-248 [MEDLINE: 16034009]
5. Wanner C, Krane V, Ruf G, Marz W, Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney International - Supplement 1999;56(Suppl 71):S222-6. [MEDLINE: 10412782]
6. Chang JW, Lee MS, Kin SB, Yang WS, Park SK, Lee SK, et al. Simvastatin decreased high-senstive c-reactive protein (hs-CRP) and increased serum albumin in hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology 2001;12 (Program & Abstracts):353A. [CENTRAL: CN-00444750]
7. * Chang JW, Yang WS, Min WK, Lee SK, Park JS, KimSB. Effects of simvastatin on high-sensitivity C-reactive protein and serumal bumin in hemodialysis patients. American Journal of Kidney Diseases 2002;39(6):1213-1217 [MEDLINE: 12046033]
8. Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei LD, Denmacker PN, Kolsters G, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. Journal of Internal Medicine 2005;257(5):438-445 [MEDLINE: 15836660] (Pubitemid 40604548)
9. Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei LD, Denmacker PN, Kolsters G, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. Journal of Internal Medicine 2005;257(4):438-445 [MEDLINE: 15836660] (Pubitemid 40604548)
10. Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei LD, Denmacker PN, Kolsters G, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. Journal of Internal Medicine 2005;257(5):438-445 [MEDLINE: 15836660] (Pubitemid 40604548)
11. Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. American Journal of Kidney Diseases 2007; Vol.49, issue 6:776-785 [MEDLINE: 17533020] (Pubitemid 46802930)
12. Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy 2005;25(3):335-344 [MEDLINE: 15843280] (Pubitemid 40300320)
13. Fiorini F, Patrone E, Castelluccio A. Clinical investigation on the hypolipidemic effect of Simvastatin versus Probucol in hemodialysis patients. Clinica Terapeutica 1994;145(9):213-217 [MEDLINE: 7813167] (Pubitemid 24359773)
14. * Harris KP, Wheeler DC, Chong CC, Atorvastatin in CAPD Study Investigators, Continuous ambulatory peritoneal dialysis. A placebo controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney International 2002;61(4):1469-1474 [MEDLINE: 11918754]
15. Wheeler D, Harris KPG, UK CAPD Investigators. A placebo-controlled trial examining the efficacy and safety of atorvastatin in dyslipidaemic patients undergoing CAPD [abstract]. Nephrology Dialysis Transplantation 2001;16(6):A196. [CENTRAL: CN-00448350]
16. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Effects of fluvastatin on leg arterial stiffness in hemodialysis patients with type 2 diabetes mellitus [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):148A. [CENTRAL: CN-00445833]
17. * Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation 2002;17(8):1513-1517 [MEDLINE: 12147804]
18. * Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca C. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Annals of Pharmacotherapy 2008;42(1):9-15. [MEDLINE: 18000162]
19. Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca CJ. Atorvastatin can safely and effectively improve cholesterol and contemporary measures of cardiovascular risks in hemodialysis patients. [abstract no: SU-PO374]. Journal of the American Society of Nephrology 2004;15(Oct):615A. [CENTRAL: CN-00583640]
20. Lins RL, Carpentier YA, Clinical Investigators Study Group. Plasma lipids and liporoteins during atorvastatin (atvs) up-titration in hemodialysis patients with hyperlipidemia: a placebo-controlled study [abstract]. Nephrology Dialysis Transplantation 2002;17(Suppl 1):124. [CENTRAL: CN-00509325]
21. * Lins RL, Matthys KE, Billiouw JM, Dratwa M, Dupont P, Lameire NH, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clinical Nephrology 2004;62(4):287-294 [MEDLINE: 15524059]
22. Robson R, Collins J, Johnson R, Kitching R, Searle M, Walker R, et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. Journal of Nephrology 1997;10(1):33-40. [MEDLINE: 9241623] (Pubitemid 27132478)
23. Robson R, Collins J, Kitchings R, Searle M, Walker R, Sharpe N, et al. A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. Journal of the American Society of Nephrology 1994;5 (3):526. [CENTRAL: CN-00550525]
24. Robson RA, Collins J, Walker RJ, MacMahon S. A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:530. [CENTRAL: CN-00509440]
25. * Walker RJ, Sutherland WH, Walker HL, MaMahon S, Robson RA. Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group. Nephrology Dialysis Transplantation 1997;12(1):87-92. [MEDLINE: 9027779]
26. Walker RJ, Sutherland WHF, Walker H, Robson RA, MacMahon SA. The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (cet) activity in renal failure (rf ) [abstract]. 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong. 1995: 28. [CENTRAL: CN-00461958]
27. * Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases 2002;39(2):283-290 [MEDLINE: 11840368]
28. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases 2002;39(2):283-290 [MEDLINE: 11840368] (Pubitemid 34174250)
29. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. American Journal of Kidney Diseases 2002;39(2):283-290 [MEDLINE: 11840368] (Pubitemid 34174250)
30. Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian Journal of Urology & Nephrology 2005;39(6):503-510 [MEDLINE: 16303728] (Pubitemid 41722034)
31. * Stegmayr BG, Brännström M, Bucht S, Crougneau V, Dimeny E, Ekspong A, et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian Journal of Urology & Nephrology 2005;39(6):489-497 [MEDLINE: 18161210]
32. Stegmayr BG, Brannstrom M, Bucht S, Dimeny E, Ekspong A, Granroth B, et al. Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna, Austria. 2001:134. [CENTRAL: CN-00447841]
33. Stegmayr BG, Nasstrom BG, Brannstrom M, Bucht S, Dimeny E, Gosch J, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract no: A0828]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):161A. [CENTRAL: CN-00447842]
34. Stegmayr BG, Nasstrom BG, Brannstrom M, Bucht S, Dimeny E, Granroth B, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):268A. [CENTRAL: CN-00583406]
35. * Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARPI) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases 2005;45(3):473-484 [MEDLINE: 15754269]
36. Baigent C, UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]. Journal of the American Society of Nephrology 2002;13(September, Program&Abstracts): 437a. [CENTRAL: CN-00444305]
37. * Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United KingdomHeart and Renal Protection (UK-HARPI) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases 2005;45(3):473-484 [MEDLINE: 15754269]
38. Baigent C, UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts): 437a. [CENTRAL: CN-00444305]
39. * Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United KingdomHeart and Renal Protection (UK-HARPI) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases 2005;45(3):473-484 [MEDLINE: 15754269]
40. Baigent C, UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts): 437a. [CENTRAL: CN-00444305]
41. * Akcicek F, Ok E, Duman S, Kursad S, Unsal A, Alev M, et al. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study. Advances in Peritoneal Dialysis 1996; 12:261-265 [MEDLINE: 8865916]
42. * Hufnagel G, Michel C, Vrtovsnik F, Queffeulou G, Kossari N, Mignon F. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. Nephrology Dialysis Transplantation 2000;15(5):684-688 [MEDLINE: 10809811]
43. * Li PK, Mak TW, Lam CW, Lai KN. Lovastatin treatment of dyslipoproteinemia in patients on continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International 1993;13 Suppl 2:S428-30. [MEDLINE: 8399631]
44. * Malyszko J, Malyszko JS, Hryszko T, Brzosko S, Mysliwiec M. Simvastatin and markers of endothelial function in patients undergoing continuous ambulatory peritoneal dialysis. International Journal of Tissue Reactions 2002;24(3):111-115 [MEDLINE: 12635864]
45. * Nishikawa O, Mune M, Miyano M, Nishide T, Nishide I, Maeda A, et al. Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney International - Supplement 1999;71:219-221 [MEDLINE: 10412781]
46. * Nishizawa Y, Shoji T, Emoto M, Kawaskai K, Konishi T, Tabata T, et al. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clinical Nephrology 1995;43 (4):268-277 [MEDLINE: 7606882]
47. * Tani M, Inagaki M, Oguchi K. Favorable effects of long-term low-dose pravastatin administration on lipid metabolism in chronic hemodialysis patients with hypercholesterolemia. Journal of the Showa Medical Association 1999;59(1):22-27 [EMBASE: 1999206546]
48. *Wanner C, Horl WH, Luley CH, Wieland H. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney International 1991;39(4):754-760 [MEDLINE: 2051734]
49. * Wanner C, Lubrich-Birkner I, Summ O, Weiland H, Schollmeyer P. Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients. Nephron 1992;62(1):40-46 [MEDLINE: 1436290]
50. * Zhu XP, Li J, Liu FY, Liu YH. Effects of Simvastatin in continuous ambulatory peritoneal dialysis patients with hyperlipidemia. Bulletin of Hunan Medical University 2000;25(2):154-156 [MEDLINE: 12212206]
51. Fellstrom B, Holdaas H, Jardine AG, Rose H, Schmieder R, Wilpshaar W, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data fromthe AURORAstudy. Kidney & Blood Pressure Research 2007;30(5):314-322 [MEDLINE: 17671394] (Pubitemid 47482063)
52. Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Armstrong J, et al. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events - the AURORA study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):713. [CENTRAL: CN-00509186]
53. Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients - Design and rationale of the AURORA study. Current Controlled Trials in Cardiovascular Medicine 2005;6:8. [EMBASE: 2005487466] (Pubitemid 41535314)
54. Study of Heart and Renal protection (SHARP). http://www.nrr.nhs.uk/ search.htm accessed August 2004.
55. Anonymous. Study of Heart and Renal Protection (SHARP). SHARP Study [http://www.ctsu.ox.ac.uk/~sharp/] 2003.
56. Blankestijn PJ, Vos PF, Rabelink TJ, van RijnHJ, JansenH, Koomans HA. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. Journal of the American Society of Nephrology 1995;5(9):1703-1708 [MEDLINE: 7780060]
57. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-2043 [MEDLINE: 17986697] (Pubitemid 350074801)
58. Costa J, Borges M, David C, Vas Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332(7550):1115-1124 [MEDLINE: 16585050] (Pubitemid 44480873)
59. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286-1291 [MEDLINE: 7718048] (Pubitemid 24340510)
60. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. Journal of the American Society of Nephrology 2007;18(10):2644-2648 [MEDLINE: 17656472]
61. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serumPO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Journal of the American Society of Nephrology 2001;12(10):2131-2138 [MEDLINE: 11562412] (Pubitemid 32880350)
62. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality. An overview of randomized trials. JAMA 1997;278(4):313-321 [MEDLINE: 9228438]
63. House AA, Wells GA, Donnelly JG, Nadler SP, Hebert AA. Effect of high flux vs low flux hemodialysis on homocysteine, lipoprotein(a) and lipid profiles: A prospective, randomized trial [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts): 211A. [CENTRAL: CN-00401331]
64. Jungers P, Massy ZA, Khoa TN, Fumeron C, Labrunie M, Lacour B, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrology Dialysis Transplantation 1997;12(12):2597-2602 [MEDLINE: 9430858] (Pubitemid 27520681)
65. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney International 2003;63(3):793-808. [MEDLINE: 12631061] (Pubitemid 36315558)
66. Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. American Journal of Cardiology 2003;91(4A):9B-13B. [MEDLINE: 12615293] (Pubitemid 36263243)
67. Kong SX, Crawford SY, Gandhi SK, Seeger JD, Schumock GT, Lam NP, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials. Clinical Therapeutics 1997;19(4):778-797 [MEDLINE: 9377621]
68. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ 1994;308(6925):367-372 [MEDLINE: 8043072]
69. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis . BMJ 2003;326(7404):1423-1428 [MEDLINE: 12829554]
70. Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia). 1996.
71. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291(4):451-459 [MEDLINE: 14747502] (Pubitemid 38129749)
72. Mallamaci F, Zoccali C, TripepiG, Fermo I, Benedetto FA, Cataliotti A, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney International 2002;61(2):609-613 [MEDLINE: 11849403] (Pubitemid 34102603)
73. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid lowering therapy in patients with renal disease. Kidney International 1995;48(1):188-198 [MEDLINE: 7564077]
74. United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed May 2007).
75. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-2497 [MEDLINE: 11368702]
76. Willis NS, Mitchell R, Higgins GY, Webster AC, Craig JC. Cochrane Renal Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2008, Issue 1. Art. No.: RENAL (accessed January 2009).
77. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic Effects of Statins:Benefit Beyond Cholesterol Reduction? A Meta-Regression Analysis.. Journal of American College of Cardiology 2005;46:1855-1862. (Pubitemid 41579807)
78. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. New England Journal of Medicine 1990;323(16):1112-1119 [MEDLINE: 2215579] (Pubitemid 20370733)
79. Saltissi D, Morgan C, Knight B, Chang W, Rigby R, Westhuyzen J. Effect of lipid-lowering dietary recommendations on the nutritional intake and lipid profiles of chronic peritoneal dialysis and hemodialysis patients. American Journal of Kidney Diseases 2001;37(6):1209-1215 [MEDLINE: 11382690] (Pubitemid 32525157)
80. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney International 2002;61(1):297-304. [MEDLINE: 11786112] (Pubitemid 34075157)
81. Sica DA, Gehr TW. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient. Current Opinion in Nephrology & Hypertension 2002;11(2):123-133 [MEDLINE: 11856903]
82. Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease - beyond lowering cholesterol. Annals of Pharmacotherapy 2000;34(12):1432-1439 [MEDLINE: 11144702]
83. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336(7645):645-651 [MEDLINE: 18299289]
84. United States Renal Data System. USRDS 2002 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. http://www.usrds.org/adr.htm 2003.
85. Navaneethan SD, Shrivastava R. HGM CoA reductase inhibitors (statins) for lowering cholesterol in dialysis patients. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD004289]
86. Navaneethan SD, Shrivastava R. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004289.pub2]